Drugs & Targets Verana Health and COTA merge to accelerate research-ready oncology real-world evidence January 16, 2026Vol.52 No.02
Drugs & Targets UAMS Winthrop P. Rockefeller Cancer Institute expands OnCore to strengthen clinical trials January 16, 2026Vol.52 No.02
A planned randomized trial will ask an intriguing question: Do COVID vaccines potentiate checkpoint inhibitors? January 09, 2026Vol.52 No.1By Sara Willa Ernst and Jacquelyn Cobb
Trials & Tribulations How a Montefiore Einstein screening program is changing the history of lung cancer in the Bronx January 09, 2026Vol.52 No.1By Brendon M. Stiles
Cancer Policy NIH agrees to review hundreds of denied or shelved grant applications January 09, 2026Vol.52 No.1By Claire Marie Porter
Cancer Policy House passes three-year extension of ACA subsidies with bipartisan support January 09, 2026Vol.52 No.1By Claire Marie Porter
Cancer Policy Merck & Co. drug for treating NSCLC awarded FDA priority voucher January 09, 2026Vol.52 No.1By Claire Marie Porter
Cancer Policy FDA-mandated report finds “insufficient data” to determine safety of PFAS in cosmetics January 09, 2026Vol.52 No.1By Claire Marie Porter
Cancer Policy Journal retracts decades-old study that determined glyphosate, widely used herbicide, as safe January 09, 2026Vol.52 No.1By Sara Willa Ernst
Cancer Policy CMS awards $50 billion for rural health care after states compete for funding January 09, 2026Vol.52 No.1By Sara Willa Ernst
